Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion

ObjectiveTo investigate the safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion.MethodTwo hundred patients with gastric cancer with serosal invasion who received neoadjuvant therapy from January 2012 to December 20...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ju-Li Lin, Jian-Xian Lin, Jun Peng Lin, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-bin Wang, Jun Lu, Qi-Yue Chen, Chang-Ming Huang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2022-01-01
Ráidu:	Frontiers in Immunology
Fáttát:	gastric cancer camrelizumab (SHR-1210) neoadjuvant chemotherapy tumor regression rate pCR
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.783243/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!